Diabetes Articles
What is gestational diabetes?
The term gestational diabetes (GD) refers to diabetes that is diagnosed during pregnancy. Current estimates place between 3% to 25% of all pregnant women to be at risk for gestational diabetes, which has significant consequences for both the fetus and the mother. Many women also develop type 2 diabetes mellitus after GD, which further compounds the need to identify the risks associated with this disease. To date, there has been no causal link established between sugar consumption and the development of GD because sugar consumption plays close to no role in influencing insulin resistance, which is the key mechanism that establishes GD.
Risks of gestational diabetes
As a pregnancy progresses throughout the trimesters, insulin resistance tends to increase in mothers that have GD. High blood sugar levels occur when the insulin-producing pancreas can no longer compensate for the resistance. There are, however, a multitude of known risk factors, and these include being under the age of 25 years; a history of type 2 diabetes mellitus or previous gestational diabetes; race, with those of African heritage particularly at risk; being overweight; having hypertension; polycystic ovarian syndrome; and chronic steroid consumption. These risk factors are used for early detection in the assessment of pregnant mothers who are prone to GD. Tackling the presence of high blood sugar levels is crucial in the early stages of fetal development, so as to ensure the organs develop normally. As mentioned above, being overweight or obese with a Body Mass Index (BMI) above 25 kg/m2 has significant bearing in predisposing pregnant women to suffer from GD.
One reason for the misconception that sugar causes GD may come from the fact that there may be excess carbohydrate intake in individuals with the disease. Excessive consumption of dessert foods, such as cake, cookies, and other confectionaries that tend to be major part of the diets of some obese individuals can lead to the false assumption that sugar and gestational diabetes have a causal link.
—
Disclaimer: Please note that the contents of this community article are strictly for informational purposes and should not be considered as medical advice. This article, and other community articles, are not written or reviewed for medical validity by Canadian Insulin or its staff. All views and opinions expressed by the contributing authors are not endorsed by Canadian Insulin. Always consult a medical professional for medical advice, diagnosis, and treatment.
GLP-1 Receptor Agonists: Exploring Their Potential in Opioid Addiction Treatment
Summary GLP-1 receptor agonists (GLP-1RAs) show potential in treating opioid addiction by reducing cravings and relapse in animal models. While some studies indicate promising results, further research in humans is…
Exploring the Potential of GLP-1 Receptor Agonists in Mitigating Amphetamine-Induced Behaviors: A Comprehensive Review
Summary: GLP-1 receptor agonists (GLP-1RAs) show promise in reducing amphetamine-induced behaviors, including hyperactivity and addiction-related preferences. Preclinical studies using Exendin-4 (Ex-4) have demonstrated its ability to decrease dopamine release in…
How to Get a Synjardy Savings Card and Save on Your Prescription
Summary: The Synjardy Savings Card helps eligible patients save on their prescription costs, often reducing co-pays to as low as $10 per month. This guide explains how to apply, use…
Synjardy 12.5 mg/1000 mg: How It Works to Control Blood Sugar
Summary: Synjardy 12.5 mg/1000 mg is a powerful combination medication for managing type 2 diabetes. Blending empagliflozin and metformin targets insulin resistance and blood sugar regulation simultaneously. This comprehensive approach…
What Is Synjardy Used For? Breaking Down Its Role in Treatment
Summary: Synjardy is a powerful combination medication used to manage type 2 diabetes effectively. Combining empagliflozin and metformin helps lower blood sugar levels and lessen the risk of diabetes-related complications.…
How Synjardy Weight Loss Impacts Your Diabetes Journey
Summary: Synjardy weight loss can be a helpful benefit for individuals with Type 2 diabetes. By combining empagliflozin and metformin, Synjardy not only helps control blood sugar but also promotes…
How to Recognize and Address Synjardy Side Effects
Summary: Synjardy is commonly used to manage Type 2 diabetes by improving blood sugar control. While it is effective, it may cause side effects such as nausea, UTIs, and yeast…
GLP-1 Receptor Agonists: A New Frontier in Combating Cocaine Addiction
Summary: Discover how GLP-1 receptor agonists are emerging as a potential treatment for cocaine addiction, offering hope for effective intervention.Cocaine addiction remains a significant public health issue, with limited effective…
Metformin: A Promising Non-Invasive Therapy for Geographic Atrophy in Age-Related Macular Degeneration
Summary: Metformin, a commonly used medication for diabetes, shows promise as a non-invasive treatment for geographic atrophy (GA), a severe form of age-related macular degeneration (AMD). Recent studies suggest metformin…
Semaglutide Shows Promise in Smoking Cessation for Patients with Type 2 Diabetes
Summary: Semaglutide shows promise in helping patients with type 2 diabetes quit smoking. A study found it reduced tobacco use disorder-related medical visits and the need for smoking cessation medications.…
When Will Retatrutide Be Available? Insights into the Future of Diabetes and Obesity Care
Summary: Retatrutide is an innovative weight loss medication in Phase 3 trials, designed to target three key hormones to aid in weight loss and improve metabolic health. With its unique…
How Does Retatrutide Work? A Deep Dive into Its Triple Receptor Action
Summary: Retatrutide, a groundbreaking multi-receptor agonist, targets GLP-1, GIP, and glucagon receptors to tackle obesity, type 2 diabetes, and metabolic disorders. Addressing multiple pathways offers comprehensive benefits in blood sugar…